Cipla launches Daptomycin for Injection

26 Sep 2019 Evaluate

Cipla has launched Daptomycin for Injection, 500mg/vial, single-dose vial (for intravenous use only), AP-rated generic equivalent of Cubicin for Injection in the United States. According to IQVIA (IMS Health), Cubicin for Injection (daptomycin for injection) had US sales of approximately $606 Million for the 12-month period ending June 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1510.10 20.95 (1.41%)
11-Dec-2025 14:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.45
Dr. Reddys Lab 1271.80
Cipla 1510.10
Zydus Lifesciences 924.75
Lupin 2082.60
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×